DANA-FARBER CANCER INSTITUTE

Becker's 2024 list highlights hospitals & health systems excelling in oncology, recognized for advanced clinical trials & research. Notable institutions include AdventHealth, Allina Health, Arkansas Children's, Atlantic Health System, Banner MD Anderson Cancer Center, Baylor Scott & White Health, Boston Medical Center, Brown University Health, Children's Health, Children's Hospital Colorado, Children’s Hospital Los Angeles, Children’s Hospital of Orange County, Children's Hospital of Philadelphia, Children's Nebraska, ChristianaCare, City of Hope Comprehensive Cancer Center, Cleveland Clinic, Connecticut Children’s, Covenant Health, Dana-Farber Cancer Institute, Dartmouth Health, DeTar Hospital Cancer Center, Duke Health, El Paso Children's Hospital, Emory Healthcare, Endeavor Health, Fred Hutchinson Cancer Center/UW Medicine, Geisinger, Hackensack Meridian Health, Huntsman Cancer Institute at the University of Utah, Inova, Jefferson Health, Johns Hopkins, Jupiter Medical Center, Keck Medicine of USC, Laredo Medical Center, Lehigh Valley Health Network, MUSC Health, MaineHealth, Massachusetts General Hospital, Mayo Clinic, MedStar, MemorialCare, Memorial Sloan Kettering Cancer Center, Michigan Medicine, Mount Sinai Health System, Nebraska Medicine, New York-Presbyterian Hospital-Columbia and Cornell, Northwestern Medicine, Novant Health, OSF HealthCare, OU Health, Ochsner Health, Ohio State University Comprehensive Cancer Center, Oregon Health & Science University Hospital, Orlando Health, Penn Medicine, Providence Alaska Medical Center, Providence Cancer Institute of Oregon, Providence South Division Cancer Institute, Queen's Health System, RWJBarnabas Health and Rutgers Cancer Institute, Renown Health, Rochester Regional Health, Roper St. Francis Healthcare, Roswell Park Comprehensive Cancer Center, Sanford Health, Sarasota Memorial Health Care System, Scripps Health, St. Jude Children's Research Hospital, Stanford Medicine, Stanford Medicine Children's Health, Sutter Health, Swedish Cancer Institute, Sylvester Comprehensive Cancer Center at University of Miami, Tampa General Hospital, Texas Children's Hospital, UC Davis Health, UCLA Health, UCSF Health, UK HealthCare, UNM Health System, UVA Health, UW Health, UMass Memorial Health, University of Alabama Birmingham Hospital, University of Chicago Medical Center, University of Colorado Cancer Center-UCHealth University of Colorado Hospital, University Hospitals, University of Iowa Health Care, University of Kansas Health System, University of Texas MD Anderson Cancer Center, University of Vermont Health Network, Vanderbilt University Medical Center, Virtua Health, WVU Cancer Institute, WellSpan Health, Yale New Haven Health.

Sehgal et al reported nivolumab plus ipilimumab activity in aggressive thyroid carcinoma, with objective responses in 9.4% of radioiodine-refractory DTC, 30% in ATC, and 0% in MTC. NRAS variants correlated with poorer survival. No treatment-related deaths occurred.

Genetics and biomarkers are crucial in prostate cancer care, but not all patients benefit equally due to clinical trial diversity issues and healthcare access barriers. Efforts to include diverse populations in trials and overcome insurance barriers are ongoing, aiming to optimize treatment efficacy and effectiveness.

Jonathan Rosenberg discusses BL-B01D1, a bispecific antibody-drug conjugate targeting EGFR and HER3 in advanced urothelial cancer, showing a 40% response rate in previously treated patients, and NKT2152, a HIF2a inhibitor for renal cell carcinoma, with a 26% response rate but potential hypoxia risks due to its long half-life.

Dr. William K. Oh appointed medical director of Smilow Cancer Hospital at Greenwich Hospital, leading oncology services and precision medicine. His expertise in genitourinary cancers and commitment to multidisciplinary care aim to enhance cancer services in lower Fairfield and Westchester counties.

Four NCI-designated cancer centers form Cancer AI Alliance (CAIA) with $40M+ funding from AWS, Deloitte, Microsoft, NVIDIA. CAIA aims to apply responsible AI to cancer data, ensuring security while transforming research and care. Fred Hutch Cancer Center leads, with CAIA expected to operate by end of 2024 and produce insights by 2025.

Kite, a Gilead Company, will present 18 studies at the 66th ASH Annual Meeting, showcasing CAR T-cell therapy's efficacy in blood cancers. Key highlights include durable responses and manageable safety profiles for anito-cel in relapsed/refractory multiple myeloma, long-term survival data for Yescarta and Tecartus in various blood cancers, and advancements in next-generation CAR T-cell therapies like KITE-753.

William K. Oh, MD, appointed Medical Director of Smilow Cancer Hospital at Greenwich Hospital and Director of Precision Medicine for Yale Cancer Center. He will lead oncology services and develop integrated care teams, focusing on precision medicine and expanding access to multidisciplinary cancer care. Dr. Oh brings extensive experience in genitourinary oncology and has published nearly 400 peer-reviewed works.

Casdatifan, a HIF-2α inhibitor, showed promising efficacy and tolerability in metastatic clear cell renal cell carcinoma (ccRCC) patients, with an objective response rate of 31.3% and disease control rate of 81.3% in the ARC-20 study. The maximum tolerated dose was not reached, and 50 mg twice daily was selected for dose expansion. Casdatifan's potential as a future treatment option for kidney cancer is supported by these findings.